GlassScriptPhysician profile
Ashwini Ammunje
NPI 1891088563
$2,735.68
in general payments reported to CMS, 2019-2025
29 companies · $1,276 in 2025
The $1,276 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $66.49 · 2021: $67.35 · 2022: $56.90 · 2023: $284 · 2024: $509 · 2025: $1,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,044 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,044.22 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $358.78 | 2024-2025 | Otezla, Repatha, Krystexxa |
| Corcept Therapeutics | $269.02 | 2025 | Korlym |
| Novo Nordisk INC | $248.71 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $237.46 | 2019-2025 | Octrode, Freestyle Libre 2, Freestyle Libre 3 |
| Pfizer INC. | $224.84 | 2019-2021 | |
| Lilly USA, LLC | $208.78 | 2020-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $186.97 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $136.42 | 2022-2024 | |
| Biosense Webster, INC. | $116.90 | 2019 | |
| Shield Therapeutics INC | $111.19 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $80.60 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Ultragenyx Pharmaceutical INC. | $67.91 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $58.50 | 2023 | Nexletol, Contrave, Onzetra Xsail |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.00 | 2025 | Jardiance |
| Exact Sciences Corporation | $41.14 | 2023-2025 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $38.26 | 2019-2025 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $38.05 | 2025 | Zoryve |
| Inspire Medical Systems, INC. | $32.21 | 2025 | Inspire |
| Medtronic, INC. | $30.00 | 2025 | Closurefast |
| Allergan, INC. | $23.81 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.08 | 2019 | |
| Abiomed | $23.01 | 2024 | Impella |
| Nevro Corp. | $22.95 | 2023 | Senza |
| Janssen Pharmaceuticals, INC | $22.71 | 2023 | Xarelto |
| Tolmar, INC. | $22.33 | 2025 | Jatenzo |
| Eisai INC. | $17.23 | 2025 | |
| Merck Sharp & Dohme LLC | $15.98 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.53 | 2019 | |
| Advanced Oxygen Therapy INC. | $11.31 | 2025 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwini Ammunje listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.